BiPar Sciences Announces Clinical Data on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting

-- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors --

BRISBANE, Calif., May 15, 2008 -- BiParSciences, Inc., a privately held biopharmaceutical company developingnovel cancer therapies, today announced that data supporting its leadPARP inhibitor, BSI-201, will be presented at the 2008 American Societyof Clinical Oncology annual meeting in Chicago.

Findings willbe presented from the first in human Phase 1 study of BSI-201, asmall-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as amonotherapy in subjects with advanced solid tumors. BiPar will alsopresent a Phase 1b study evaluating BSI-201 in combination withtopotecan, gemcitabine, temozolomide and carboplatin/paclitaxel insubjects with advanced solid tumors. The primary objective of theserespective studies is to assess the safety profile of BSI-201 when usedas a monotherapy and in combination with cytotoxic chemotherapy insubjects with measurable disease.

The schedule of poster presentations is as follows:

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.

Contact:

Eric Malek
Vice President, Corporate Development
650-635-0165
emalek@biparsciences.com
www.biparsciences.com

Stacie D. Byars
WeissComm Partners
206-660-2588
sdbyars@wcpglobal.com




back to Press Releases